MARLBOROUGH, Mass.,
Sept. 26, 2018 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its proprietary
self-delivering RNAi (sd-rxRNA®) therapeutic platform today
announced that it will present a poster entitled, "The Use of
Self-delivering RNAi to Enhance NK Cell Cytotoxicity," at the 16th Annual
Discovery on Target Conference. The conference is being held
September 25-28, 2018 at the Sheraton
Boston in Massachusetts.
Logo -
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
Date: Wednesday, September
26, 2018
Location: Sheraton Boston
Title: The Use of Self-delivering RNAi to Enhance NK Cell
Cytotoxicity
View the poster here:
http://investors.rxipharma.com/events-and-presentations/posters
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's discovery and
research efforts are focused on developing sd-rxRNA therapeutic
compounds to be used with an Adoptive Cell Transfer (ACT) approach.
This process uses immune cells, such as T-lymphocytes that are
isolated from the patient or retrieved from allogeneic immune cell
banks, and then expanded and in some cases processed to express
tumor-binding receptors. Our approach introduces a new and
important step in ex-vivo processing of the immune cells where
sd-rxRNA is used to eliminate the expression of immunosuppressive
receptors or proteins from the therapeutic immune cells, making
them less sensitive to tumor resistance mechanisms and thus
improving their ability to destroy the tumor cells. Essentially, we
aim to maximize the power of our sd-rxRNA therapeutic compounds by
weaponizing therapeutic immune effector cells to attack cancer and
ultimately provide patients battling terminal cancers with a
powerful new treatment option that goes beyond current treatment
modalities.
For additional information, visit the Company's website,
www.rxipharma.com and follow us on Twitter @RxiPharma.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are neither historical facts nor
assurances of future performance. These statements are based only
on our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements
as a result of a number of important factors, including the safety
and efficacy of our product candidates, future success of our
clinical trials and scientific studies, our ability to enter into
strategic partnerships and the future success of these strategic
partnerships, the availability of funds and resources to pursue our
research and development projects and general economic conditions.
Our Annual Report on Form 10-K and subsequent Quarterly Reports on
Form 10-Q include detailed risks under the caption "Risk Factors"
that may affect our business, results of operations and financial
condition. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact RXi Pharmaceuticals Corporation
Tamara McGrillen
Tel: +1 508-929-3646
Email: tmcgrillen@rxipharma.com
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-new-data-from-its-immuno-oncology-program-using-sd-rxrna-therapeutic-compounds-targeting-intracellular-checkpoint-cbl-b-in-nk-cells-at-the-16th-annual-discovery-on-target-conference-300719117.html
SOURCE RXi Pharmaceuticals Corporation